5-chloro-4’-(trifluoromethyl)[1,1’-biphenyl]-2-carboxylic acid | 273727-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-4’-(trifluoromethyl)[1,1’-biphenyl]-2-carboxylic acid
• 英文别名: 4-Chloro-2-(4-trifluoromethylphenyl)benzoic acid；4-chloro-2-[4-(trifluoromethyl)phenyl]benzoic acid
• CAS: 273727-25-6
• 化学式: C₁₄H₈ClF₃O₂
• 分子量: 300.665
• InChiKey: BNOSVWSVSXMETM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ent-5-(aminomethyl)-5-(1-methyl-1H-imidazol-2-yl)imidazolidine-2,4-dione hydrochloride 、 5-chloro-4’-(trifluoromethyl)[1,1’-biphenyl]-2-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以54%的产率得到5-chloro-N-{[4-(1-methyl-1H-imidazol-2-yl)-2,5-dioxoimidazolidin-4-yl]methyl}-4'-(trifluoromethyl)[biphenyl]-2-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS
  [FR] HYDANTOÏNAMIDES SUBSTITUÉS UTILISÉS EN TANT QU'ANTAGONISTES D'ADAMTS7

  摘要：

  本申请涉及式(I)所示的取代脒酰胺作为ADAMTS7拮抗剂，涉及它们的制备过程，以及它们单独或组合用于治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠心病(CAD)、外周血管病(PAD)、动脉闭塞性疾病或血管成形术后的再狭窄。R1是氢、烷基、环烷基、杂环烷基、杂芳基或苯基；R2是氢、氰基、卤素、烷基亚磺酰基、烷基、环烷基或烷氧基；R3、R4、R5、R6、R7和R8独立的是氢、卤素、烷基或烷氧基；大多数基团可被选择性地取代；条件是至少R2、R3、R4中的一个为H；X1、X2、X3、X4、X5和X6独立的是N或C；条件是每个环中最多只有一个X是N。

  公开号：

  WO2021094436A1
• 作为产物：
  描述：

  5'-Chloro-2'-methyl4-trifluoromethyl-biphenyl 、 potassium permanganate 、 水 在 乙酸乙酯 、 Brine 、 Sodium sulfate-III 作用下， 以 叔丁醇 为溶剂， 反应 16.0h， 以to give the title compound (24 g) as white crystals的产率得到5-chloro-4’-(trifluoromethyl)[1,1’-biphenyl]-2-carboxylic acid
  参考文献：
  名称：

  Use of therapeutic benzamide derivatives

  摘要：

  本发明涉及使用式（I）的治疗苯甲酰胺类化合物作为微粒体甘油三酯转移蛋白（MTP）抑制剂，用于治疗肥胖和餐后高脂血症。

  公开号：

  US20040044008A1

文献信息

• Muscarinic Acetylcholine Receptor Antagonists
  申请人：Laine Dramane I.

  公开号：US20080249127A1

  公开（公告）日：2008-10-09

  Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

  提供了肌氨酸乙酰胆碱受体拮抗剂及其使用方法。
• Heterocyclic amide compounds as apolipoprotein b inhibitors
  申请人：Takasugi Hisashi

  公开号：US20050038035A1

  公开（公告）日：2005-02-17

  The present invention relates to a compound of the formula (I) wherein R 1 is optionally substituted aryl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A 1 ) m1 -(A 2 ) m2 -; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及一种化合物，其分子式为（I），其中R1为可选取代芳基；R2为可选取代芳基、可选取代杂环芳基、可选取代较低环烷基、可选取代芳氧基、可选取代芳基磺酰基、乙烯基、氨基甲酰基、保护羧基或保护氨基；环A为由可选取代芳基或可选取代杂环芳基衍生的二价残基；X为由环烷烯、萘、不饱和的5或6元杂单环基衍生的二价残基，每种残基均可选取代，以及取代苯基；Y为-(A1)m1-(A2)m2-；Z为直接键或哌嗪，或其盐。本发明的化合物及其盐能抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于高循环Apo B水平引起的疾病或病症的药物。
• Amide compounds
  申请人：——

  公开号：US20040157866A1

  公开（公告）日：2004-08-12

  The present invention relates to compounds of the formula (I) wherein X 1 is wherein R 1 , R 2 and R 10 are independently hydrogen or a suitable substituent; R 11 and R 12 are independently hydrogen or a suitable substituent; R is unsaturated 5 to 6-membered heteromonocyclic group; A is direct bond or —NH—; X 2 is monocyclic arylene, unsaturated 5 to 6-membered heteromonocyclic group or cycloalkenylene; Y is bivalent group selected from ethylene, trimethylene and vinylene, wherein CH 2 is optionally replaced by NH or O, and CH is optionally replaced by N; and Z is —(CH 2 ) n —, —CO—(CH 2 ) m —, —CH═CH— or —CO—NH—, wherein n is 1, 2 or 3 and m is 1 or 2, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B. 1

  本发明涉及公式（I）的化合物，其中X1为R1，R2和R10分别为氢原子或适当的取代基；R11和R12分别为氢原子或适当的取代基；R为不饱和的5至6元杂环单环基；A为直接键或—NH—；X2为单环芳烃，不饱和的5至6元杂环单环基或环烯基；Y为乙烯基，三亚甲基或乙烯基中选择的双价基团，其中CH2可以被NH或O替代，CH可以被N替代；Z为—（ ）n—，—CO—（ ）m—，—CH=CH—或—CO—NH—，其中n为1、2或3，m为1或2，或其盐。本发明的化合物抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于Apo B循环水平升高而导致的疾病或病症的药物。
• Benzamide derivatives and their use as ApoB-100 secretion inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06552022B1

  公开（公告）日：2003-04-22

  The invention relates to therapeutic benzamide compounds of formula (I) wherein A, X, Z, R1, Y, R2, R3, are as defined herein, and physiologically acceptable salts, solvates or derivatives thereof. The present invention also provides pharmaceutical compositions, processes for the preparation of compounds of formula (I) and their use in the treatment of conditions mediated by ApoB-100 regulation.

  本发明涉及公式（I）的治疗苯甲酰胺类化合物，其中A、X、Z、R1、Y、R2、R3如本文所定义，并且其生理上可接受的盐、溶剂化合物或衍生物。本发明还提供了药物组合物、制备公式（I）化合物的方法以及它们在治疗由ApoB-100调节介导的情况下的使用。
• SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS
  申请人：Bayer Aktiengesellschaft

  公开号：EP3822268A1

  公开（公告）日：2021-05-19

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R 1 is hydrogen, alkyl, cycloalkyl, 5- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl or phenyl; R 2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R 2 , R 3 , R 4 is H; X 1 , X 2 , X 3 , X 4 , X 5 , X 6 are independently N or C; with the proviso that in each ring maximal one X is N.

  本申请涉及作为 ADAMTS7 拮抗剂的式 (I) 取代的 hydantoinamides、其制备工艺、单独使用或联合使用以治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠状动脉疾病 (CAD)、外周血管疾病 (PAD)、动脉闭塞性疾病或血管成形术后再狭窄。 R 1 是氢、烷基、环烷基、5-6 元杂环烷基、5-10 元杂芳基或苯基；R 2 是氢、氰基、卤素、烷基磺酰基、烷基、环烷基或烷氧基；R 3、R 4、R 5、R 6、R 7、R 8 独立地是氢、卤素、烷基或烷氧基；X1、X2、X3、X4、X5、X6 独立地为 N 或 C，但每个环中最多一个 X 为 N。